Review Article

Dual Role of MSC-Derived Exosomes in Tumor Development

Rou Zhao, 1,2 Xinke Chen, 1 Hui Song, 1 Qingli Bie, 1,3 and Bin Zhang 1,3

1Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
2Department of Microbiology, Qingdao University Life Science College, Qingdao, Shandong, China
3Institute of Forensic Medicine and Laboratory Medicine, Jining Medical University, Jining, Shandong, China

Correspondence should be addressed to Qingli Bie; xiaobie890101@163.com and Bin Zhang; zhb861109@163.com

Received 15 May 2020; Revised 8 July 2020; Accepted 24 August 2020; Published 9 September 2020

Academic Editor: Aijun Wang

Copyright © 2020 Rou Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mesenchymal stem cells (MSCs) are a class of adult stem cells derived from the mesoderm. They can self-renew, have multidirectional differentiation potential, and can differentiate into a variety of mesenchymal tissues. MSCs can produce a large number of exosomes, which can mediate information exchange and transmission between cells in the tumor microenvironment under conditions of rest or stress. Recent studies have reported conflicting findings regarding the effect of MSC-derived exosomes on tumors. Some studies have suggested that MSC-derived exosomes can promote tumor growth and metastasis, but others have reported that they can inhibit tumor cell growth. Here, we investigate the two sides of the debate regarding the effect of MSC-derived exosomes on tumors and analyze the reasons for the divergent findings.

1. Background

Mesenchymal stem cell- (MSC-) derived exosomes were first studied in a mouse model of myocardial ischemia/reperfusion injury in 2010 [1]. Under transmission electron microscopy, MSC-derived exosomes exhibit characteristic circular shapes of varying sizes [2]. Cross-talk between the tumor microenvironment and tumor seems to be crucial for tumor growth and development. Related studies have shown that MSCs produce exosomes, which may act as paracrine mediators by transferring signal molecules that regulate tumor cell proliferation, angiogenesis, and metastasis by controlling many cellular pathways. At present, whether MSC-derived exosomes promote or inhibit tumors remains controversial, and many studies have reported inconsistent conclusions. As listed in Tables 1 and 2, emerging evidence indicates that MSC exosomes may transfer proteins, messenger RNA, and microRNA to recipient cells, thereby affecting tumor cell growth, metastasis, and drug response. Here, we review the relationships identified in recent years between MSC-derived exosomes and tumor development, with an emphasis on how MSC-derived exosomes appear to play two contrasting roles, and discuss the mechanisms of these roles.

2. Characteristics of MSC-Derived Exosomes

MSCs have attracted considerable attention in recent years because of their capacities for immunoregulation and tissue repair and their implications for tumor development. MSCs are a class of mesoderm pluripotent stem cells, with pluripotent differentiation potential [3, 4], which are preferentially present in the niches of the perivascular spaces of almost all human tissues and organs, including the dental pulp [5], bone marrow [6], adipose tissue [7], neonatal placenta [8], amniotic membrane, and umbilical cord [9]. Under examination with an inverted microscope, MSCs appear as relatively uniform fibroblast-like cells with rotational filling adherent growth [10]. Under examination with an inverted microscope, MSCs appear as relatively uniform fibroblast-like cells with rotational filling adherent growth [10]. The characteristics of MSCs change depending on the pathophysiological state of the tissue in which they are located [11]. Complex interactions between MSCs and molecules in the surrounding tissue microenvironment lead to various results, depending on the type and duration of tissue damage and the intensity of the associated local inflammation [8–12]. Receptors for multiple factors are expressed on the surface of MSCs, which can effectively migrate to the site of inflammation or cancer because of the inflammatory factors in the microenvironment of such sites [13]. MSCs secrete a variety of inflammatory factors, such
as MCP-1, IL-6, and IL-8, which contribute to the directed migration of MSCs [14]. Moreover, they have been found to migrate to tumors and evolve into tumor-associated MSCs (TA-MSCs) [15, 16], which secrete a plethora of growth factors, cytokines, chemokines, and structural protein components to communicate with tumor cells and promote tumor development by activating cell proliferation and invasion, angiogenesis, and other processes [17]. Recent studies involving the use of MSCs as cell carriers in targeted tumor therapy have shown that genetically modified MSCs can continuously and stably produce therapeutic factors that play roles in tumor inhibition or tumor sites [18]. Current experimental models have indicated that MSCs may promote or inhibit the regulation of various tumors; however, the mechanism by which MSCs regulate tumor cells remains unclear.

Exosomes are small membrane vesicles that contain complex RNA and proteins. They are typically discoid vesicles 30–100 nm in diameter and were first identified in sheep reticulocytes in 1983 [19]. Exosomes are secreted by a variety of cells, including endothelial cells, immune cells, platelets, and smooth muscle cells. Exosomes are mainly derived from the intracellular polyvesicles formed by intracellular lysosomal particles, which are released into the extracellular matrix by the fusion of the extracorporeal membrane of polyvesicles with the cell membrane. When secreted into receptor cells by host cells, exosomes regulate the biological activities of receptor cells by carrying proteins, nucleic acids, lipids, and other molecules that have effects on receptor cells [20, 21]. Under the condition of physiological or pathological changes, exosomes can mediate intercellular communication and regulate the biological activities of recipient cells through their specific cargo [22]. The formation of exosomes begins with an inward budding of the cell membrane, resulting in the formation of early endosomes that incorporate membrane protein; they then transform into multivesicular bodies (MVBs) with a dynamic subcellular structure [23]. As shown in Figure 1, MVBs can be generated through two mechanisms: endosomal sorting complex required for transport (ESCRT) and independent ESCRT [24]. The ESCRT mechanism is activated by a set of cytoplasmic protein complexes that recognize ubiquitin-modified membrane proteins. Ubiquitin markers identified by the first ESCRT compound, ESCRT 0, enrich the inner body membrane and pass the ubiquitinated substances to ESCRT I and ESCRT II. Tsg101 in ESCRT I recognizes disulfide bonds and induces endosomal membrane depression; bonds are subsequently cut by ESCRT I to form MVBs [25]. However, MVBs can be formed without ESCRT. For example, the accessory protein, alg-2 interacting protein X, can directly bind with intracellular adaptor proteins to participate in the formation of exosomes. The production of these ESCRT-independent MVBs can promote MVB formation through tetraspans [26] and ceramide-induced cell membrane budding [27]. MVBs can be fused with lysosomes that have degraded and recycled content.

### Table 1: Tumor/cancer-promoting cargoes transported by MSC-derived exosomes.

| Cargo type | Source of exosome | Target cancer | Outcome | Exosomal cargo/pathway | Reference |
|------------|-------------------|--------------|---------|------------------------|-----------|
| Protein    | Human umbilical cord MSCs | Gastric cancer cells | Promotion of cell growth and migration | Activated Akt pathway | [47] |
| Protein    | Human bone marrow MSCs | Gastric cancer cells | Promotion of tumor growth | Activated kinase1/2 (ERK1/2) pathway | [50] |
| Protein    | Human bone marrow MSCs | Osteosarcoma and gastric cancer cells | Promotion of tumor growth | Activated Hedgehog pathway | [49] |
| Protein    | Human breast cancer AMSCs | Breast cancer cells | Promotion of cell growth | Activated Hippo signaling pathway | [51] |
| Protein    | Human MSCs | Gastric cancer cells | Conferral of drug resistance | Activated CaM-Ks and Raf/MEK/ERK pathways | [53] |
| Protein    | Human adipose-derived MSCs | Breast cancer cells | Promotion of cell migration | Activated Wnt pathway | [52] |
| Protein    | Human and mouse tumor-educated MSCs | Breast cancer cells | Acceleration of cancer progression | TGF-b, C1q, and semaphorins | [44] |
| Protein    | MSCs | Nasopharyngeal carcinoma cells | Facilitation of tumor progression | FGF19 | [43] |
| Protein    | MSCs | Breast cancer cells | Support of cell reorganization and growth | MMP-2 | [41] |
| Protein    | SD human MSCs | Breast cancer cells | Support of cancer cell proliferation and metastasis | miR-21 and 34a | [36] |
| Protein    | Gastric cancer tissue-derived MSCs | Gastric cancer cells | Promotion of cell proliferation and migration | miR-221 | [37] |
| Protein    | Glioma-associated MSCs | Glioblastoma cells | Enhancement of aggressiveness | miR-1587 | [35] |
| Protein    | LNC-MSCs | Multiple myeloma cells | Promotion of proliferation and suppression of apoptosis | LINC00461 | [39] |

Stem Cells International
and can also be fused with the plasma membrane and secreted outside of the cell. Exosomes are vital for intercellular communication and play a major role in paracrine. Exosomes can directly bind to specific ligands of target cells through surface receptors, triggering intracellular signal transduction or transferring exosome surface receptors to target cells [28]. Multimolecular complexes can also be formed on the surface of target cell membranes to change the structure of the lipid bilayer and directly endorse exosomes, or a mass of membrane fusion proteins in the target cell membrane and exosome can overcome the energy barriers of plasma membrane fusion and achieve membrane fusion [29]. Exosomes can be separated through differential centrifugation, use of an ExoQuick exosome extraction kit, immunomagnetic bead sorting, sucrose density gradient ultracentrifugation, microfluidic separation, and other methods [30, 31].

3. The Mechanism by Which MSC-Derived Exosomes Promote Tumor Progression

3.1. The Role of MSC-Derived Exosomal MicroRNA. As shown in Figure 2, MSC-derived exosomes can promote tumor growth through a variety of mechanisms. Valadi et al. first found that exosomes contain both mRNA and microRNA, which can be delivered to another cell and be functional in the new location, and proposed that this RNA be called “exosomal RNA” [32]. Exosomes containing microRNAs are thought to regulate communication between stem cells and cancer cells [33]. Several recent studies have shown that exosomal miRNAs secreted by stem cells affect the biological behavior of cancer cells [34]. To analyze the effects of MSC-derived exosomal microRNAs on cancer cells, Figueras et al. [35] analyzed the exosomal content and identified miR-1587 as a mediator of the exosomal-promoted effects of glioma-associated human MSCs (hMSCs) on glioma cells. Vallabhaneni and collaborators observed that exosomes released by serum-derived hMSCs could induce breast cell proliferation by transferring miRNA-21 and miR-34a [36]. In a study by Wang et al. [37], miR-221 was identified as a highly specific microRNA in exosomes from gastric cancer tissue-derived MSCs; the exosomes mediated the transfer of functional miR-221 to gastric cancer cells and promoted their proliferation and migration. However, Roccaro et al. [38] found that exosomal microRNA content differed between normal bone marrow-derived MSCs (BM-MSCs) and MM BM-MSCs; because of their relatively high content of the tumor suppressor miR-15a, exosomes derived from MM

### Table 2: Tumor/cancer-inhibiting cargoes transported by MSC-derived exosomes.

| Cargo type | Source of exosome | Target cancer/cells | Outcome | Exosomal cargo/pathway | Reference |
|------------|------------------|---------------------|---------|-------------------------|-----------|
| miRNA      | Human bone marrow MSCs | Osteosarcoma cells | Inhibition of tumor cell migration | miR-143 | [68] |
|            | MSCs              | Glioma cells and glioma stem cells | Reduction of cell migration and self-renewal | miR-124 and miR-145 | [55] |
|            | Human MSCs        | Breast cancer cells | Suppression of angiogenesis | miR-100 | [57] |
|            | MSCs              | Prostate cancer cells | Suppression of cancer progression | miR-145 | [54] |
|            | MSCs              | Breast cancer cells | Suppression of angiogenesis | miR-16 | [58] |
|            | Human bone marrow MSCs | Breast cancer cells | Promotion of dormancy | miR-23b | [59] |
|            | MSCs              | Breast cancer cells | Stimulation of cycling quiescence and dormancy | miR-222/223 | [60] |
| miRNA      | Human bone marrow MSCs | Prostate cancer cells | Inhibition of cell migration and invasion | miR-143 | [69] |
|            | Human adipose-derived MSCs | Hepatocellular carcinoma | Cancer cells rendered sensitive to chemotherapeutic agents | miR-122 | [18] |
|            | Normal bone marrow MSCs | Multiple myeloma | Inhibition of tumor promotion | — | [38] |
| miRNA      | MSCs              | Glioblastoma multiforme cells | Reversal of chemoresistance | Anti-miR-9 | [66] |
|            | MSCs              | Glioma | Reduction of progression and metastasis | miR-146b | [67] |
|            | MSCs              | Pancreatic cancer cells | Inhibition of cancer activity | miR-1231 | [61] |
|            | MSCs              | Glioma | Suppression of progression | miR-133b | [56] |
| siRNA      | MSCs              | Bladder cancer cells | Induction of apoptosis and necrosis | PLK-1 siRNA | [70] |
| Pathway    | MSCs              | Human leukemia cells | Enhancement of apoptosis | Activated caspase pathway | [62] |
| Drug       | MSCs              | Breast cancer cells | Reduction in viability | PTX | [71] |
|            | Human MSCs        | HeLa cells | Ablation of cancer cells | Iron oxide | [72] |
BM-MSCs promoted MM tumor growth, but normal BM-MSC exosomes inhibited the growth of MM cells. In recent years, multiple long noncoding RNAs (lncRNAs) have been involved in the regulation of MM development. In a study by Deng et al. [39], LINC00461 was transmitted by MSC-derived exosomes to multiple myeloma cells and enhanced

**Figure 1:** Exosome biogenesis and secretion. Cell membrane inward budding leads to the formation of early endosomes, and these transform into multivesicular bodies (MVBs) with a dynamic subcellular structure. MVBs can be fused with lysosomes or the plasma membrane and secreted exosomes. Finally, exosomes release cargo such as DNA, microRNA, and proteins to cancer cells through (a) direct fusion with recipient cell plasma, (b) surface protein binding, or (c) endocytosis.

**Figure 2:** Promotional roles of MSC-derived exosomes in tumors. MSC-derived exosomes can promote tumor growth and cell migration and confer drug resistance on gastric cancer by activating the Akt, ERK1/2, CaM-Ks, and Hedgehog pathways and transporting miR-221 to cancer cells. MSC-derived exosomes support multiple myeloma progression by shuttling LINC00461. Moreover, MSC-derived exosomes support breast cancer cell proliferation, metastasis, and reorganization through Hippo and Wnt pathways and by delivering exosomal TGF-b, C1q, semaphorins, MMP-2, miR-21, and miR-34a. MSC-derived exosomes promote osteosarcoma growth through the Hedgehog pathway. MSC-derived exosomes facilitate nasopharyngeal carcinoma progression through the delivery of FGF19. MSC-derived exosomes enhance the aggressiveness of glioblastoma and growth of glioma stem cells through the delivery of miR-1587.
cell proliferation and suppressed apoptosis by modulating microRNA/BCL-2 expression.

3.2. Role of MSC-Derived Exosomal Proteins. Proteins are one of the major components of exosomes [40]. Protein analysis of MSC-derived exosomes has demonstrated the presence of MMP-2 and MSC-specific markers, including CD90 and ecto-5′-nucleotidase. Yang et al. found that MSC-derived exosomes containing MMP-2 enzymes can alter cell function and recombine the cancer microenvironment, which is a new approach for improving cancer cell growth [41]. Because it is associated with poor outcomes of cancer, FGF19 may serve as a therapeutic target for treating cancer. FGF19 activity is regulated by the binding and activation of FGFR4, and this FGF19-FGFR4 interaction plays a role in carcinogenesis [42]. FGF19 was found to be highly expressed in MSC-derived exosomes, and exosomes stimulate NPC progression [43]. FGF19-FGFR4 interaction plays a role in carcinogenesis. Furthermore, Biswas and collaborators determined that MSC-derived exosomes but not exosomes from tumor cells had high levels of TGF-b and C1q, which enhance the immunosuppressive activity and M2 polarization of myeloid cells [44]. Our research team found that umbilical cord MSC-derived exosomes promote cell proliferation by transporting Wnt4 [45, 46].

3.3. Key Pathways Mediated by MSC-Derived Exosomes. Regardless of the type of molecule transported by MSC-derived exosomes, important pathways of target cells are activated by such transportation. In recent years, the effect of MSC-derived exosomes on tumor progression has been extensively studied. Among the proposed mechanisms, pathway activation mediated by MSC-derived exosomes has been widely investigated. Akt is one of the main downstream effects of PI3K and activates multiple signal phosphorylation substrates that significantly affect tumor cell growth and cell cycle progression. Gu et al. demonstrated that MSC-derived exosomes induce Akt phosphorylation, thereby enhancing the epithelial–mesenchymal transition (EMT) and self-renewal capacity of gastric cancer cells [47]. It has been reported that human bone marrow MSCs exist in the tumor microenvironment, participate in the formation of the tumor microenvironment, and interact with cancer cells [48]. To understand the mechanism of human bone marrow MSC-(hBMSC-) derived exosomes on tumor growth, Qi et al. [49] examined the signaling pathway of exosomes derived from MSCs isolated from human bone marrow tissue and found that hBMSC-derived exosomes promoted MG63 and SGC7901 cell growth through the activation of the Hedgehog signaling pathway. It was also demonstrated that hBMSC-derived exosomes enhance vascular endothelial growth factor (VEGF) expression in gastric carcinoma cells by activating the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway [50]. Adipocytes are the most abundant stromal cell component in breast cancer tissues, and Wang et al. [51] used exosomes isolated from in vitro MSC-differentiated adipocytes to systematically investigate the effects of adipocyte exosomes on tumor development in a breast cancer model. They discovered that MSC-derived exosomes enhanced breast cancer cell proliferation and migration and protected breast cancer cells from serum derivation or chemotherapeutic drug-induced apoptosis through activation of the Hippo signaling pathway in vitro. In addition, exosomes were found to contribute to in vivo tumor growth in a mouse xenograft model. Exosomes from human adipose-derived MSCs were demonstrated to promote migration through the Wnt signaling pathway in a breast cancer cell model [52]. Growing evidence suggests that MSCs protect tumor cells from chemotherapeutic drugs by generating multiple factors, recycling macromolecules, and activating certain signal cascades. Ji et al. [53] found that MSC-derived exosomes induce drug resistance in gastric cancer cells by activating the CaMKs/Raf/MEK/ERK pathway.

4. Antitumor Effect of MSC-Derived Exosomes

4.1. Direct Antitumor Effects of MSC-Derived Exosomes. Although most studies concerning MSC-derived exosomes have focused on their role in promoting tumor progression, a considerable body of other research has demonstrated that MSC-derived exosomes have significant antitumor effects (Figure 3). Takahara and collaborators indicated that microRNA-145 mediates the inhibitory effect of adipose-derived stem cells on androgen-independent prostate cancer [54]. Lee et al. demonstrated that the miR-124 and miR-145 delivered by MSC-derived exosomes significantly reduce the migration of glioma cells and the self-renewal of glioma stem cells [55]. Moreover, Xu et al. discovered that MSC-derived exosomes shuttle microRNA-133b to inhibit glioma progression through the Wnt/β-catenin signaling pathway by targeting EZH2 [56]. In addition, MSC-derived exosomes also significantly downregulate the expression of VEGF in breast cancer cells in vitro and in vivo. Pakravan et al. [57] hypothesized that the exosomal transfer of miRNAs from MSCs may affect tumor angiogenesis. Their findings suggest that MSC exosomal transfer of miR-100 suppresses in vitro angiogenesis through modulation of the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells. This hypothesis was confirmed by another group. Lee et al. [58] demonstrated that MSC-derived exosomes significantly downregulate the expression of VEGF in breast cancer cells by transferring antiangiogenic molecule miR-16. Dormant breast cancer metastasizes into the bone marrow after prolonged dormancy and interacts with MSCs in the bone marrow. Ono et al. [59] reported that exosomes from bone marrow MSCs contain miR-23b, which promotes dormancy in metastatic breast cancer cells. Similarly, exosomal miR-222/223 was confirmed to stimulate cycling quiescence and early breast cancer dormancy in the bone marrow [60]. In addition, Shang et al. found that MSC-derived exosomal miRNA-1231 inhibits the activity of pancreatic cancer [61], and Liu et al. [62] demonstrated that MSC-derived exosomes enhance imatinib-induced apoptosis in human leukemia cells through activation of the caspase signaling pathway.

4.2. Antitumor Effects of Modified MSC-Derived Exosomes. Because of their membrane structure, exosomes have potential to serve as natural carriers of therapeutic agents for
cancer therapy. Recent research has confirmed that modified exosomes enhance the cancer-killing efficacy and cancer-targeting ability of drugs, thereby increasing the effectiveness of individual cancer therapies [63]. Glioblastoma (GBM) is the most aggressive and common type of primary brain tumor, has extremely poor prognosis, and is highly resistant to conventional chemotherapy [64, 65]. The application of miR-targeting therapeutics in GBM treatment is an area of extensive research. Munoz et al. [66] demonstrated that the delivery of anti-miR-9 by MSC-derived exosomes to a GBM could reduce miR-9 expression and the resistance of GBM to TMZ. Katakowski et al. transfected MSCs with the miR-146b expression plasmid and reported that intratumor injection of exosomes derived from miR-146b-expressing MSCs significantly reduced glioma xenograft growth [67]. Identical to GBM, hepatocellular carcinoma (HCC) is also highly resistant to conventional chemotherapy. Considering that microRNA-122 is a crucial promoter of the chemical sensitivity of HCC cells, Lou et al. [18] aimed to determine whether adipose tissue-derived MSC (AMSC) exosomes can be used for miR-122 delivery. The results indicated that miR-122 exported from AMSC-derived exosomes enhances the chemical sensitivity of HCC. Similarly, miR-targeting therapies have also been applied to treat other types of tumors. As demonstrated by Shimbo et al. [68], the delivery of synthetic miR-143 formed by MSC-derived exosomes significantly reduces the migration of osteosarcoma cells. Che et al. also focused on miR-143 and investigated the effect of hBMSC-derived exosomal miR-143 on prostate cancer; they found that miR-143 negatively targets TFF3 to suppress cancer progression [69]. Synthetic small stem RNA (siRNA), which can be used to selectively inhibit a target gene, has great potential in cancer treatment. MSC-derived exosomes can be used as delivery vehicles for synthetic siRNA. In the study by Greco et al. [70], treating bladder cancer cells with exosomes electroporated with PLK-1 siRNA successfully knocked down PLK-1 mRNA and protein, resulting in apoptosis and necrosis of bladder cancer cells. Kalimuthu et al. observed that MSC exosomes can be used as drug delivery vehicles, and thus, they could deliver PTX to breast cancer cells [71]. Moreover, Altanerova et al. [72] found that MSC-derived iron oxide exosomes can be combined with magnetotherapy for target resection of tumor cells.

5. The Role of Tumor Cell-Derived Exosomes on MSCs

Extensive research confirms that tumor-derived exosomes contain molecular and genetic signals that are able to induce modifications in MSCs and transform them from normal nutrition to tumorigenic, which produce factors necessary for tumor growth [73, 74]. Lindoso et al. reported, for
example, that renal cancer stem cell-derived exosomes promote MSC migration to the tumor and induce expression of the tumorigenic phenotype in these MSCs [75]. Another study has shown that exosomes produced by primary or metastatic colorectal cancer can reprogram mesenchymal stem cells, inducing morphological and functional changes that are beneficial to tumor growth and metastasis [76]. Exosomes from prostate or breast cancer cells can induce bone marrow mesenchymal stem cell differentiation into myeloid fibroblasts that overexpress alpha smooth muscle actin [77]. Moreover, exosomes derived from AML cells can transform MSCs into leukemia growth-permitting cells and inhibit normal hematopoiesis in vivo [78]. Yeon et al. proved melanoma-derived exosomes trigger endothelial to mesenchymal transition followed by the induction of cancer-associated fibroblasts [79]. The overall conclusion of these experiments is that MSCs reprogrammed by tumor-derived exosomes are essential to tumor progression.

6. Discussion

Researchers have discovered that MSC-derived exosomes may play two roles in the tumor microenvironment [80], but few reports have addressed how and why this is the case. The complex cellular and molecular interactions between MSCs and the surrounding tissue microenvironment may lead to different results. MSCs can migrate to tumors and evolve into diverse types of cells, such as TA-MSCs and CAFs [15]. Cancer-derived signals can regulate the phenotype of cancer-recruited MSCs, making them a part of the cancer mass; these cancer-recruited MSCs possess characteristics that are distinct from other tissue-derived MSCs or BM-MSCs [81]. Typically, the difference between noncancer-related MSCs and CAFs may be accounted for by the responses of cytokines and exosomes produced in the tumor microenvironment [82]. In addition, MSCs are more frequently detected in cancer tissues than in adjacent normal tissues, which have a greater proliferation capacity [83]. Depending on the source, exosomes exhibit distinct characteristics and secretory factors, which may be related to their biogenesis and targeting and putative immune functions [84]. This indicates the necessity of assessing the source of exosomes formed by the microenvironment. Moreover, exosome-secreting factors represent the roles of exosomes in establishing and altering the tumor microenvironment.

In general, the effects of MSC-derived exosomes in promoting or inhibiting tumors and cancers seem to depend on the source of MSC-derived exosomes; depending on the tumor or cancer microenvironment, MSCs may be transformed into CAFs or TA-MSCs. As suggested in some studies, glioma-associated human MSC-derived exosomes enhance the aggressiveness of glioma [35]. However, the exosomes derived from BM-MSCs carry antitumor miRNAs, which significantly reduce the growth of the glioma xenograft [67]. Coincidentally, exosomes released by human breast cancer AMSCs induce breast cell proliferation and migration [36–51]. Exosomes derived from TA-MSCs accelerate breast cancer progression [44], but hBMSC-derived exosomes have been confirmed to stimulate cycling quiescence and breast cancer dormancy after metastasizing to the bone marrow [59, 60]. Rocco et al. [38] noted that BM-MSC-derived exosomes in patients with multiple myeloma supported the progression of multiple myeloma cells, whereas exosomes isolated from normal hBMSCs might metastasize to the low mir-15a level, thus inhibiting the development of multiple myeloma cells. In several studies, tumor growth inhibition has been observed when MSC-derived exosomes are introduced into the established tumors or the cultured tumor cells. By contrast, numerous studies have demonstrated that MSC-derived exosomes promote tumor growth when the MSCs are cocultured with tumor cells. Exosomes isolated from a coculture of MSCs/breast cancer cells were found to enhance the growth of cancer cells [41]. Meanwhile, exosomes prepared from the supernatant of BM-MSCs were demonstrated to suppress the in vitro angiogenesis of breast cancer cells [57]. Moreover, Karaoz et al. [85] reported that the proliferation rate of cancer cells significantly increased when they were cocultured with WJ-MSCs but not when they were cocultured with cancer cells treated with pure MSC-derived exosomes.

The bioactive molecules shuttled by MSC-derived exosomes reprogram recipient cells, and the contents of MSC-derived exosomes have been determined to include protein, microRNA, IncRNA, liposomes, and other molecules. Thus, another mechanism related to the two-sided effects of MSC-derived exosomes on tumors may be related to the differences in the components contained in MSC-derived exosomes. As shown in Figure 4, for example, MSC-derived exosomes play a role in transporting MMP-2 [41], miR-21, and miR-34a [36], which have been demonstrated to be involved in cancer cell survival [86] and proliferation [2, 87], and MMP-2, which has also been demonstrated to be overexpressed in breast cancer cells; additionally, the high expression of MMP-2 is associated with poor prognosis [88, 89]. Although MSC-derived exosomes can inhibit cancer cells by transporting miR-100 and miR-16, among others, miR-100 induction could counteract the tumor-promoting effect of EMT-induced transcription factors [90], and miR-16 was demonstrated to downregulate VEGF expression [91]. Moreover, TGF-β, C1q, and semaphorins have been found to be involved with MSC-derived exosomes in promoting breast cancer development [44]; however, miR-23b [59] and miR-222/223 [60] were found to be transported by MSC-derived exosomes to suppress breast cancer development. Similarly, MSC-derived exosomes that transport miR-1587 [35] increase the proliferation and self-renewal of GSCs, whereas shuttled miR-146b [67] inhibits glioma growth. In general, MSC-derived exosomes transport different cargoes that may have different effects on tumors.

Finally, the effects of MSC-derived exosomes may vary depending on the tumor type or stage of tumor development. For example, many studies have revealed that MSC-derived exosomes facilitate gastric cancer growth and migration (Table 1) and that exosomes derived from gastric cancer cells stimulate CAF differentiation of MSCs [92]. However, MSC-derived exosomes appear to only exhibit an inhibitory effect on prostate cancer, as indicated in Table 2. MSC-derived exosomes can inhibit cancer cell migration and invasion [69] or
suppress cancer progression [54]. According to relevant research, MSC-derived exosomes are more inclined to inhibit angiogenesis and metastasis in breast cancer [57] and stimulate cycling quiescence and dormancy of cancer cells, preventing metastasis [59, 60]. By contrast, for HCC [18] and GBM [66], MSC-derived exosomes are more likely to affect chemoresistance.

7. Conclusion

As a newly discovered intercell information transmission tool, MSC-derived exosomes play crucial roles in tumor development and are a major focus of recent research. The regulatory effect of MSC-derived exosomes on tumors remains debated and has three potential mechanisms. First, the source of MSC-derived exosomes may be influential; MSCs may undergo transformation in the tumor microenvironment or cancer microenvironment, and CAF- and TA-MSC-derived exosomes promote tumor development, whereas MSC-derived exosomes from healthy tissue could inhibit tumor growth. Second, another mechanism may be related to the differences in the components contained in MSC-derived exosomes. Finally, MSC-derived exosomes from different tumors have different effects on different tumors. Of particular note, MSC-derived exosomes are ideal carriers for tumor-targeted therapy and display several unique advantages, including simple acquisition, easy access to recipient cells, and strong plasticity. Consequently, thorough research is necessary for the rapid advancement of MSC-derived exosome treatments.

Abbreviations

CAFs: Cancer-associated fibroblasts
MSCs: Mesenchymal stem cells

Figure 4: MSC-derived exosomes shuttle various bioactive molecules to inhibit or promote tumor growth. Black areas are inhibitory bioactive molecules, and white areas are promotional bioactive molecules.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

BZ and QB are responsible for the conception and idea and drafting of the paper. RZ, XC, and HS are responsible for the writing, review, and revision of the manuscript. All authors read and approved the final manuscript. All of the authors are aware of and agree to the content of the paper and their being listed as a coauthor of the paper.

Acknowledgments

We thank the members of Zhang Lab for helpful discussion. This study was supported by grants from the National Natural Science Foundation of China (Nos. 81702439 and 81802446), Tai Shan Young Scholar Foundation of Shandong Province, Shandong Provincial Natural Science Foundation.
References

[1] G. Raposo and W. Stoorvogel, "Extracellular vesicles: exosomes, microvesicles, and friends," Journal of Cell Biology, vol. 200, no. 4, pp. 373–383, 2013.

[2] L. B. Frankel, N. R. Christoffersen, A. Jacobsen, M. Lindow, A. Krog, and A. H. Lund, "Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells," Journal of Biological Chemistry, vol. 283, no. 2, pp. 1026–1033, 2008.

[3] G. Lazennec and P. Y. Lam, "Recent discoveries concerning the tumor - mesenchymal stem cell interactions," Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1866, no. 2, pp. 290–299, 2016.

[4] P. Bianco, P. G. Robey, and P. J. Simmons, "Mesenchymal stem cells: revisiting history, concepts, and assays," Cell Stem Cell, vol. 2, no. 4, pp. 313–319, 2008.

[5] R. Hass, C. Kasper, S. Bohm, and R. Jacobs, "Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC," Cell Communication and Signaling, vol. 9, no. 1, p. 12, 2011.

[6] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells," Science, vol. 284, no. 5411, pp. 143–147, 1999.

[7] A. I. Caplan, "Mesenchymal stem cells," Journal of Orthopaedic Research, vol. 9, no. 5, pp. 641–650, 1991.

[8] A. Uccelli, L. Moretta, and V. Pistoia, "Mesenchymal stem cells in health and disease," Nature Reviews Immunology, vol. 8, no. 9, pp. 726–736, 2008.

[9] P. Bianco, X. Cao, P. S. Frenette et al., "The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine," Nature Medicine, vol. 19, no. 1, pp. 35–42, 2013.

[10] S. M. Ridge, F. J. Sullivan, and S. A. Glynn, "Mesenchymal stem cells: key players in cancer progression," Molecular Cancer, vol. 16, no. 1, p. 31, 2017.

[11] Y. Shi, J. Su, A. I. Roberts, P. Shou, A. B. Rabson, and G. Ren, "How mesenchymal stem cells interact with tissue immune responses," Trends in Immunology, vol. 33, no. 3, pp. 136–143, 2012.

[12] Y. Wang, X. Chen, W. Cao, and Y. Shi, "Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications," Nature Immunology, vol. 15, no. 11, pp. 1009–1016, 2014.

[13] M. Timaner, K. K. Tsai, and Y. Shaked, "The multifaceted role of mesenchymal stem cells in cancer," Seminars in Cancer Biology, vol. 60, pp. 225–237, 2020.

[14] H. Munir, L. S. C. Ward, and H. M. McGettrick, "Mesenchymal stem cells as endogenous regulators of inflammation," in Stromal Immunology. Advances in Experimental Medicine and Biology, vol 1060, B. Owens and M. Lakins, Eds., pp. 73–98, Springer, Cham, 2018.

[15] M. Quante, S. P. Tu, H. Tomita et al., "Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth," Cancer Cell, vol. 19, no. 2, pp. 257–272, 2011.

[16] G. Ren, X. Zhao, Y. Wang et al., "CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα," Cell Stem Cell, vol. 11, no. 6, pp. 812–824, 2012.

[17] F. R. Balkwill, M. Capasso, and T. Hagemann, "The tumor microenvironment at a glance," Journal of Cell Science, vol. 125, no. 23, pp. 5591–5596, 2013.

[18] G. Lou, X. Song, F. Yang et al., "Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma," Journal of Hematology & Oncology, vol. 8, no. 1, p. 122, 2015.

[19] A. Beach, H. G. Zhang, M. Z. Ratajczak, and S. S. Kakar, "Exosomes: an overview of biogenesis, composition and role in ovarian cancer," Journal of Ovarian Research, vol. 7, no. 1, p. 14, 2014.

[20] S. Mathivanan, C. J. Fahner, G. E. Reid, and R. J. Simpson, "ExoCarta 2012: Database of exosomal proteins, RNA and lipids," Nucleic Acids Research, vol. 40, no. D1, pp. D1241–D1244, 2012.

[21] R. J. Simpson, J. W. E. Lim, R. L. Moritz, and S. Mathivanan, "Exosomes: proteomic insights and diagnostic potential," Expert Review of Proteomics, vol. 6, no. 3, pp. 267–283, 2014.

[22] M. Tkach and C. Thery, "Communication by extracellular vesicles: where we are and where we need to go," Cell, vol. 164, no. 6, pp. 1226–1232, 2016.

[23] R. M. Johnstone, M. Adam, J. R. Hammond, L. Orr, and C. Turville, "Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes)," Journal of Biological Chemistry, vol. 262, pp. 9412–9420, 1987.

[24] B. Yu, X. Zhang, and X. Li, "Exosomes derived from mesenchymal stem cells," International Journal of Molecular Sciences, vol. 15, no. 3, pp. 4142–4157, 2014.

[25] M. Colombo, C. Moita, G. van Niel et al., "Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles," Journal of Cell Science, vol. 126, no. 24, pp. 5553–5565, 2013.

[26] G. van Niel, S. Charrin, S. Simeos et al., "The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis," Developmental Cell, vol. 21, no. 4, pp. 708–721, 2011.

[27] K. Trajkovic, C. Hsu, S. Chiantia et al., "Ceramide triggers budding of exosome vesicles into multivesicular endosomes," Science, vol. 319, no. 5867, pp. 1244–1247, 2008.

[28] A. Janowska-Wieczorek, M. Majka, J. Kijowski et al., "Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment," Blood, vol. 98, no. 10, pp. 3143–3149, 2001.

[29] E. Cocucci, G. Racchetti, and J. Meloquesi, "Shedding microvesicles: artefacts no more," Trends in Cell Biology, vol. 19, no. 2, pp. 43–51, 2009.

[30] P. Li, M. Kaslan, S. H. Lee, J. Yao, and Z. Gao, "Progress in exosome isolation techniques," Theranostics, vol. 7, no. 3, pp. 789–804, 2017.

[31] B. Zhang, L. Shen, H. Shi et al., "Exosomes from human umbilical cord mesenchymal stem cells: identification, purification, and biological characteristics," Stem Cells International, vol. 2016, Article ID 1929536, 11 pages, 2016.

[32] M. Ragusa, D. Barbagallo, and M. Purrello, "Exosomes: nanoshuttles to the future of BioMedicine," Cell Cycle, vol. 14, no. 3, pp. 289–290, 2015.
with special focus on mesenchymal stem cells," Critical Reviews in Oncology/Hematology, vol. 69, no. 3, pp. 187–198, 2009.

[49] J. Qi, Y. Zhou, Z. Jiao et al., "Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth through Hedgehog signaling pathway," Cellular Physiology and Biochemistry, vol. 42, no. 6, pp. 2242–2254, 2017.

[50] W. Zhu, L. Huang, Y. Li et al., "Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo," Cancer Letters, vol. 315, no. 1, pp. 28–37, 2012.

[51] S. Wang, X. Su, M. Xu et al., "Exosomes secreted by mesenchymal stromal/stem cell-derived adipocytes promote breast cancer cell growth via activation of Hippo signaling pathway," Stem Cell Research & Therapy, vol. 10, no. 1, p. 117, 2019.

[52] R. Lin, S. Wang, and R. C. Zhao, "Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model," Molecular and Cellular Biochemistry, vol. 383, no. 1-2, pp. 13–20, 2013.

[53] R. Ji, B. Zhang, X. Zhang et al., "Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer," Cell Cycle, vol. 14, no. 15, pp. 2473–2483, 2015.

[54] K. Takahara, T. Inamoto, N. Ibi and et al., "245 MicroRNA-145 mediates the inhibitory effect of adipose-derived stem cells on androgen-independent prostate cancer," European Urology Supplements, vol. 15, no. 3, article e245, 2016.

[55] H. K. Lee, S. Finniss, S. Cazacu et al., "Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal," Oncotarget, vol. 4, no. 2, pp. 346–361, 2013.

[56] H. Xu, G. Zhao, Y. Zhang et al., "Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2," Stem Cell Research & Therapy, vol. 10, no. 1, p. 381, 2019.

[57] K. Pakravan, S. Babashah, M. Sadeghizadeh et al., "MicroRNA-100 shuttled by mesenchymal stem cell-derived exosomes suppresses in vitro angiogenesis through modulating the mTOR/HIF-1α/VEGF signaling axis in breast cancer cells," Cellular Oncology, vol. 40, no. 5, pp. 457–470, 2017.

[58] J. K. Lee, S. R. Park, B. K. Jung et al., "Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells," PLoS One, vol. 8, no. 12, article e84256, 2013.

[59] M. Ono, N. Kosaka, N. Tominaga et al., "Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells," Science Signaling, vol. 7, no. 332, article ra63, 2014.

[60] S. A. Bliss, G. Sinha, O. A. Sandiford et al., "Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow," Cancer Research, vol. 76, no. 19, pp. 5832–5844, 2016.

[61] S. Shang, J. Wang, S. Chen et al., "Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer," Cancer Medicine, vol. 8, no. 18, pp. 7728–7740, 2019.

[62] Y. Liu, B. Song, Y. Wei et al., "Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway," Cytotherapy, vol. 20, no. 2, pp. 181–188, 2018.

[63] B. You, W. Xu, and B. Zhang, "Engineering exosomes: a new direction for anticancer treatment," American Journal of Cancer Research, vol. 8, pp. 1332–1342, 2018.
F. B. Furnari, T. Fenton, R. M. Bachoo et al., “Malignant astrocytic glioma: genetics, biology, and paths to treatment,” Genes & Development, vol. 21, no. 21, pp. 2683–2710, 2007.

S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioreistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006.

J. L. Munoz, S. A. Bliss, S. J. Greco, S. H. Ramkissoon, K. L. Ligon, and P. Rameshwar, “Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity,” Molecular Therapy - Nucleic Acids, vol. 2, article e126, 2013.

M. Katakowski, B. Buller, X. Zheng et al., “Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth,” Cancer Letters, vol. 335, no. 1, pp. 201–204, 2013.

K. Shimbo, S. Miyaki, H. Ishitobi et al., “Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration,” Biochemical and Biophysical Research Communications, vol. 445, no. 2, pp. 381–387, 2014.

Y. Che, X. Shi, Y. Shi et al., “Exosomes derived from miR-143-overexpressing MSCs inhibit cell migration and invasion in human prostate cancer by downregulating TFF3,” Molecular Therapy - Nucleic Acids, vol. 18, pp. 232–244, 2019.

K. A. Greco, C. A. Franzen, K. E. Foreman, R. C. Flanagan, P. C. Kuo, and G. N. Gupta, “PLK-1 silencing in bladder cancer by siRNA delivered with exosomes,” Urology, vol. 91, pp. 241.e1–241.e7, 2016.

S. Kalimuthu, P. Gangadaran, R. L. Rajendran et al., “A new approach for loading anticancer drugs into mesenchymal stem cell-derived exosome mimetics for cancer therapy,” Frontiers in Pharmacology, vol. 9, article 1116, 2018.

U. Altanerova, M. Babincova, P. Babinec et al., “Human mesenchymal stem cell-derived iron oxide exosomes allow targeted ablation of tumor cells via magnetic hyperthermia,” International Journal of Nanomedicine, vol. 12, pp. 7923–7936, 2017.

S. Ludwig, T. Flores, M. N. Theodoraki et al., “Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer,” Clinical Cancer Research, vol. 23, no. 16, pp. 4843–4854, 2017.

T. L. Whiteside, “Exosomes and tumor-mediated immune suppression,” Journal of Clinical Investigation, vol. 126, no. 4, pp. 1216–1223, 2016.

R. S. Lindoso, F. Collino, and G. Camussi, “Extracellular vesicles derived from renal cancer stem cells induce a protumorigenic phenotype in mesenchymal stromal cells,” Oncotarget, vol. 6, no. 10, pp. 7959–7969, 2015.

L. Lugini, M. Valtieri, C. Federici et al., “Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells,” Oncotarget, vol. 7, no. 31, pp. 50086–50098, 2016.

J. A. Cho, H. Park, E. H. Lim, and K. W. Lee, “Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells,” International Journal of Oncology, vol. 40, pp. 130–138, 2011.

B. Kumar, M. García, L. Weng et al., “Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion,” Leukemia, vol. 32, no. 3, pp. 575–587, 2018.

J. H. Yeon, H. E. Jeong, H. Seo et al., “Cancer-derived exosomes trigger endothelial to mesenchymal transition followed by the induction of cancer-associated fibroblasts,” Acta Biomaterialia, vol. 76, pp. 146–153, 2018.

S. Shojaei, S. M. Hashemi, H. Ghanbarian, M. Salehi, and S. Mohammad-Yeganeh, “Effect of mesenchymal stem cell-derived exosomes on tumor microenvironment: Tumor progression versus tumor suppression,” Journal of Cellular Physiology, vol. 234, no. 4, pp. 3394–3409, 2019.

D. Trivanovic, J. Krsitic, I. O. Djordjevic et al., “The roles of mesenchymal stromal/stem cells in tumor microenvironment associated with inflammation,” Mediators of Inflammation, vol. 2016, Article ID 7314016, 14 pages, 2016.

J. C. Brune, A. Tormin, M. C. Johansson et al., “Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts,” International Journal of Cancer, vol. 129, no. 2, pp. 319–330, 2011.

Z. Sun, S. Wang, and B. C. Zhao, “The roles of mesenchymal stem cells in tumor inflammatory microenvironment,” Journal of Hematology & Oncology, vol. 7, no. 1, pp. 14, 2014.

D. Kumar, D. Gupta, S. Shankar, and R. K. Srivasta, “Biomolecular characterization of exosomes released from cancer stem cells possible implications for biomarker and treatment of cancer,” Oncotarget, vol. 6, no. 5, pp. 3280–3291, 2015.

E. Karaoz, E. Sun, and C. S. Demir, “Mesenchymal stem cell-derived exosomes do not promote the proliferation of cancer cells in vitro,” International Journal of Physiology, Pathophysiology and Pharmacology, vol. 11, pp. 177–189, 2019.

Y. Ma, W. Bao-Han, X. Lv et al., “MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation,” PLoS One, vol. 8, no. 8, article e72383, 2013.

F. Meng, R. Henson, H. Webbe–Janek, K. Ghoshal, S. T. Jacob, and T. Patel, “MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepato cellular cancer,” Gastroenterology, vol. 133, no. 2, pp. 647–658, 2007.

A. Talvensaari-Mattila, P. Pääkkö, M. Höyhtyä, G. Blan co-Sequeiros, and T. Turpeenniemi, “Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma,” Cancer, vol. 83, no. 6, pp. 1153–1162, 1998.

H. C. Li, D. C. Cao, Y. Liu et al., “Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma,” Breast Cancer Research and Treatment, vol. 88, no. 1, pp. 75–85, 2004.

D. Chen, Y. Sun, Y. Yuan et al., “miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion,” PLoS Genetics, vol. 10, no. 2, article e1004177, 2014.

E. Dejean, M. H. Renalier, M. Foisseau et al., “Hypoxia-micro RNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas,” Leukemia, vol. 25, no. 12, pp. 1882–1890, 2011.

J. Gu, H. Qian, L. Shen et al., “Gastric exosomes differentiation of derived cells to Carcinoma-Associatedfibroblasts through TGF-β/Smad Pathway,” PLoS One, vol. 7, no. 12, article e52465, 2012.